Overview
Principal investigator
Eligibility criteria
Inclusion Criteria:
* At least 18 years old at the time of signing the main study informed consent form (ICF).
* Histologically confirmed:
* Grades 1-3 WD NETs (dose escalation and dose expansion)
* Meningioma (dose expansion only)
* SSTR-positive disease, as assessed by SSTR-PET imaging
* Adequate renal, hematologic and hepatic function
Exclusion Criteria:
* Prior RPT, including Lu-177.
* Prior solid organ or bone marrow transplantation.
* Use of chronic systemic steroid therapy.
* Significant cardiovascular disease
* Resistant hypertension
* Uncontrolled diabetes
* Prior history of liver cirrhosis
* HIV, hepatitis B infection or known active hepatitis C virus infection.
* At least 18 years old at the time of signing the main study informed consent form (ICF).
* Histologically confirmed:
* Grades 1-3 WD NETs (dose escalation and dose expansion)
* Meningioma (dose expansion only)
* SSTR-positive disease, as assessed by SSTR-PET imaging
* Adequate renal, hematologic and hepatic function
Exclusion Criteria:
* Prior RPT, including Lu-177.
* Prior solid organ or bone marrow transplantation.
* Use of chronic systemic steroid therapy.
* Significant cardiovascular disease
* Resistant hypertension
* Uncontrolled diabetes
* Prior history of liver cirrhosis
* HIV, hepatitis B infection or known active hepatitis C virus infection.
For Referring Providers
Do you have a patient you think would be a good candidate for this trial? Learn more about enrolling your patient.